Results 171 to 180 of about 260,017 (286)

Dexmedetomidine infusions improve cardiovascular and renal function in anaesthetised, experimentally endotoxaemic horses

open access: yesEquine Veterinary Journal, EarlyView.
Abstract Background Dexmedetomidine infusions are beneficial in anaesthetised endotoxaemic horses when administered concurrent to endotoxin, but post‐conditioning effects are unknown. Objectives To evaluate whether a dexmedetomidine infusion is beneficial in horses administered Escherichia coli O55:B5 lipopolysaccharides (LPS) endotoxin prior to ...
Sera Lee   +4 more
wiley   +1 more source

Fatalities within seven days after equine standing sedation: A prospective, multicentre study

open access: yesEquine Veterinary Journal, EarlyView.
Abstract Background Information regarding mortality associated with standing procedures in horses is sparse. Objectives To report data from >12,000 standing sedations. Study Design Confidential, observational, prospective, multicentre, cohort study.
Miguel Gozalo‐Marcilla   +6 more
wiley   +1 more source

Risk factors for bladder calculi in patients with benign prostatic hyperplasia. [PDF]

open access: yesMedicine (Baltimore), 2017
Huang W   +6 more
europepmc   +1 more source

Warmed intravenous fluid administration attenuated a reduction in body temperature in anaesthetised horses

open access: yesEquine Veterinary Journal, EarlyView.
Abstract Background Peri‐anaesthetic hypothermia is a well‐documented complication of general anaesthesia and is associated with prolonged recovery, impaired wound healing, and delayed coagulation. Fluid warmers can be used to mitigate heat loss, but there is little evidence supporting their effectiveness in equine anaesthesia.
Miranda P. Starr   +4 more
wiley   +1 more source

Acupuncture Alleviates Allergic Rhinitis by Activating the AMPK/PGC‐1α Pathway to Attenuate Mitochondrial Oxidative Stress and Restore Epithelial Barrier Function

open access: yesFlavour and Fragrance Journal, EarlyView.
Acupuncture at Feishu (BL13), Shenshu (BL23), Yingxiang (LI20), and Dazhui (GV14) alleviates allergic rhinitis by activating the AMPK/PGC‐1α/NRF1/TFAM signalling axis. This activation improves mitochondrial biogenesis and function, reduces mtROS‐mediated oxidative stress, restores ATP production and respiratory complex I/IV activity, suppresses IgE and
Fengying Zhang   +3 more
wiley   +1 more source

Illuminating point‐of‐care diagnostics with aggregation‐induced emission biosensors

open access: yesFlexMat, EarlyView.
This review highlights the application of aggregation‐induced emission luminogens (AIEgens) in point‐of‐care (POC) diagnostics for disease biomarker detection. It systematically examines a range of biosensing platforms, including lateral flow immunoassays, microfluidic chips, and electrochemiluminescence sensors, alongside their utility in detecting ...
Danni Hu   +3 more
wiley   +1 more source

Living at genetic risk: The patient experience of Lynch syndrome

open access: yesInternational Journal of Cancer, EarlyView.
Abstract Lynch syndrome is a germline cancer predisposition syndrome caused by a variant in one of four genes. Lynch syndrome places individuals at significantly higher risk for a range of cancers, especially colorectal and endometrial. Depending on which gene is affected, the risk of ovarian, gastric, small bowel, pancreatic, biliary urothelial, brain,
Nicola Reents   +2 more
wiley   +1 more source

Bilateral Xanthogranulomatous Pyelonephritis in a Patient With Spina Bifida and Neurogenic Bladder: A Case Report. [PDF]

open access: yesAm J Case Rep
Wale DD   +9 more
europepmc   +1 more source

Diabetes Increases Immunotherapy‐Related Toxicity but Not Efficacy in Metastatic Non‐Small Cell Lung Cancer: A Multicenter Retrospective Study

open access: yesInternational Journal of Cancer, EarlyView.
ABSTRACT This multicenter retrospective study evaluated the impact of type 2 diabetes mellitus (DM) on clinical outcomes and immune‐related adverse events (irAEs) in 450 patients with metastatic non‐small cell lung cancer (NSCLC) treated with second‐line nivolumab at 17 centers between 2016 and 2024. Among these patients, 118 (26.2%) had DM.
Emre Çakır   +32 more
wiley   +1 more source

Home - About - Disclaimer - Privacy